{"id":"asp5541","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ASP5541 blocks the C5a receptor on immune cells, preventing the binding of complement component C5a and thereby reducing complement-driven inflammatory responses. This mechanism is intended to modulate excessive immune activation in inflammatory and autoimmune conditions while preserving protective immunity.","oneSentence":"ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:21:23.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (specific indications under investigation in phase 2)"}]},"trialDetails":[{"nctId":"NCT07005154","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-06-19","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":218},{"nctId":"NCT07339267","phase":"PHASE1","title":"A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-01-20","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":12},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":"Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRL-02"],"phase":"phase_2","status":"active","brandName":"ASP5541","genericName":"ASP5541","companyName":"Astellas Pharma Global Development, Inc.","companyId":"astellas-pharma-global-development-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Inflammatory and autoimmune disorders (specific indications under investigation in phase 2).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}